Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Viridian Therapeutics, Inc.\DE (VRDN) Equity Ratio (2016 - 2025)

Viridian Therapeutics, Inc.\DE has reported Equity Ratio over the past 12 years, most recently at 0.8 for Q4 2025.

  • Quarterly results put Equity Ratio at 0.8 for Q4 2025, down 11.25% from a year ago — trailing twelve months through Dec 2025 was 0.8 (down 11.25% YoY), and the annual figure for FY2025 was 0.8, down 11.25%.
  • Equity Ratio for Q4 2025 was 0.8 at Viridian Therapeutics, Inc.\DE, down from 0.87 in the prior quarter.
  • Over the last five years, Equity Ratio for VRDN hit a ceiling of 0.93 in Q3 2022 and a floor of 0.8 in Q4 2025.
  • Median Equity Ratio over the past 5 years was 0.9 (2024), compared with a mean of 0.89.
  • Biggest five-year swings in Equity Ratio: soared 44.32% in 2021 and later fell 11.25% in 2025.
  • Viridian Therapeutics, Inc.\DE's Equity Ratio stood at 0.92 in 2021, then dropped by 1.46% to 0.91 in 2022, then fell by 0.74% to 0.9 in 2023, then increased by 0.37% to 0.9 in 2024, then fell by 11.25% to 0.8 in 2025.
  • The last three reported values for Equity Ratio were 0.8 (Q4 2025), 0.87 (Q3 2025), and 0.88 (Q2 2025) per Business Quant data.